0.05Open0.05Pre Close99 Volume38 Open Interest13.50Strike Price525.00Turnover248.25%IV50.56%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0588Delta0.0542Gamma180.00Leverage Ratio-0.0313Theta0.0000Rho10.59Eff Leverage0.0010Vega
Altimmune Stock Discussion
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet